Bod Science (ASX:BOD) sold its rights to three intellectual properties to Optimus Salvus, according to a Jan. 24 filing with the Australian bourse.

The assets pertain to the rights to soft gel/S3 clinical research and data, Aqua Phase, and CLIC Protein, per the filing. The transaction consideration comprises a lump sum payment of AU$125,000 exclusive of tax, the forgiveness of debt claimed by the Aqua Phase inventors worth 2 million pounds sterling, and a 5% equity interest in Optimus Salvus.

Proceeds will form part of a deed fund and be transferred to Bod Science's creditors' trust in line with its deed of company arrangement, the filing said.